Aristada 441mg
Drug
Alkermes, Inc.
Total Payments
$1.3M
Transactions
242
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $165,777 | 1 | 0 |
| 2017 | $1.1M | 241 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 242 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects with Schizophrenia who are Inadequately Treated with Paliperidone Palmitate | Alkermes, Inc. | $828,741 | 0 |
| Pregnancy Registry Performance for Atypical Antipsychotics | Alkermes, Inc. | $319,061 | 0 |
| A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | Alkermes, Inc. | $143,400 | 0 |
| A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia | Alkermes, Inc. | $600.00 | 0 |
Top Doctors Receiving Payments for Aristada 441mg
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Richardson, TX | $1.3M | 242 |
Ad
Manufacturing Companies
- Alkermes, Inc. $1.3M
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 0
- Transactions 242
About Aristada 441mg
Aristada 441mg is a drug associated with $1.3M in payments to 0 healthcare providers, recorded across 242 transactions in the CMS Open Payments database. The primary manufacturer is Alkermes, Inc..
Payment data is available from 2017 to 2018. In 2018, $165,777 was paid across 1 transactions to 0 doctors.
The most common payment nature for Aristada 441mg is "Unspecified" ($1.3M, 100.0% of total).
Aristada 441mg is associated with 4 research studies, including "Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects with Schizophrenia who are Inadequately Treated with Paliperidone Palmitate" ($828,741).